Analysis of adverse events in a dose titration study

Area of Science:

• Clinical Pharmacology
• Drug Safety
• Biostatistics

Background:

• Dose escalation trials are common for evaluating drug efficacy.
• Analyzing adverse event data in these trials presents unique challenges compared to efficacy data analysis.
• Traditional dose-response assumptions may not hold for adverse events during dose escalation.

Purpose of the Study:

• To investigate the complexities of analyzing adverse event data from dose escalation trials.
• To highlight the limitations of standard dose-response assessments for adverse events.
• To propose a more informative approach for evaluating drug safety during titration.

Main Methods:

• Examined adverse event data from a specially designed dose escalation trial with a placebo arm and three active drug arms.
• Employed a forced titration scheme within active drug arms to vary dose escalation rates.
• Compared dose-specific incidence with time-dose-specific incidence of adverse events.

Main Results:

• The assumption of consistent adverse event occurrence across increasing doses was not applicable.
• Time effects are confounded with dose effects in dose escalation designs, making dose-response relationships preliminary.
• Time-dose-specific incidence of adverse events, incorporating titration pace, offers more valuable safety information.

Conclusions:

• Assessing dose-response relationships for adverse events in titration schemes requires a placebo arm and varied maximum doses.
• For drugs requiring titration, adverse event incidence must be reported with dosage, time, and titration pace.
• A time-dose-specific analysis is crucial for accurate drug safety evaluation during dose escalation.